Theraclone initiates TCN-032 Phase 1 trial in influenza A

August 11, 2017

"Zenyaku Kogyo is committed to develop novel therapeutics to improve human health. Through TCN-032, we hope to provide benefits to patients at high risk for influenza infection and its complications," said Kazuhiro Hashimoto, Chairman of Zenyaku Kogyo Company, Ltd. "We are excited to see the first candidate from our collaboration with Theraclone enter clinical development."

The randomized, double-blind Phase 1 dose-escalation trial in healthy adult volunteers will assess the safety profile of a single intravenous administration of TCN-032 compared to placebo. The study will enroll 40 volunteers at a single U.S. site and will also provide pharmacokinetic and immunogenicity data. Study results are expected in the first half of 2012 and are a pre-requisite for commencement of proof of concept clinical trials.

Zenyaku Kogyo has an exclusive license in the territory of Japan to Theraclone's influenza monoclonal antibody program. Theraclone retains worldwide development and commercialization rights outside of Japan.

Source: Theraclone Sciences